Current Situation and Challenges in Vitreous Substitutes by Mondelo García, Cristina et al.
REVIEW
www.mbs-journal.de
Current Situation and Challenges in Vitreous Substitutes
Cristina Mondelo-García, Enrique Bandín-Vilar, Laura García-Quintanilla,
Ana Castro-Balado, Eva M. del Amo, María Gil-Martínez, María José Blanco-Teijeiro,
Miguel González-Barcia, Irene Zarra-Ferro, Anxo Fernández-Ferreiro,*
and Francisco J. Otero-Espinar*
Vitreo-retinal disorders constitute a significant portion of treatable ocular
diseases. These pathologies often require vitreo-retinal surgery and, as a
consequence, the use of vitreous substitutes. Nowadays, the vitreous
substitutes that are used in clinical practice are mainly divided into gases (air,
SF6, C2F6, C3F8) and liquids (perfluorocarbon liquids, silicone oils, and heavy
silicone oils). There are specific advantages and drawbacks to each of these,
which determine their clinical indications. However, developing the ideal
biomaterial for vitreous substitution continues to be one of the most
important challenges in ophthalmology, and a multidisciplinary approach is
required. In this sense, recent research has focused on the development of
biocompatible, biodegradable, and injectable hydrogels (natural, synthetic,
and smart), which also act as medium and long-term internal tamponade
agents. This comprehensive review aims to cover the main characteristics and
indications for use of the extensive range of vitreous substitutes that are
currently used in clinical practice, before going on to describe the hydrogels
that have been developed recently and which have emerged as promising
biomaterials for vitreous substitution.
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1. Introduction
The vitreous humour is a transparent gel
present between the lens and the retina. It
has a volume of around 4 mL and occupies
80% of the eye volume.[1,2] It weighs around
4 g and contains approximately 99% water,
only adhering to ocular structures in the fol-
lowing parts: the macula, the optic nerve
disc, and the anterior border of the area sur-
rounding the retina.[2]
Vitreo-retinal disorders constitute a sig-
nificant portion of treatable ocular dis-
eases. The vitreous humour often becomes
dysfunctional due to opacification, lique-
faction or physical collapse, as a result
of inflammatory diseases, developmental
abnormalities, vitreous hemorrhage, tu-
mors, diabetes, or degenerative processes.
In addition, vitreous damage can also
be caused by intraocular foreign bodies
or trauma.[3] The vitreous humour de-
termines the clarity of vision meaning
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therefore that, if not treated properly, these disorders can cause
blindness. Vitreous substitutes are crucial adjuncts during vitreo-
retinal (VR) surgery for retinal diseases.[2,4,5]
Nowadays, the most common agents that are used as vitre-
ous substitutes in clinical practice boast certain advantages, in-
cluding chemical inertness and optical clarity, nonetheless, there
are also many limitations to their use.[2] In this sense, the de-
velopment and characterization of new vitreous substitutes have
played an important role in vitreo-retinal surgery. Despite the fact
that considerable efforts have been made in developing new bio-
materials for vitreous substitution in search of the perfect alter-
native that is able to overcome the disadvantages presented by the
currently available substances, further research must be per-
formed. In this regard, developing the ideal biomaterial for vit-
reous substitution continues to be one of the most significant
challenges in ophthalmology. Given the complexity of this mat-
ter, a multidisciplinary approach, which involves ophthalmic sur-
geons, pharmacists, chemists, and experts in biomaterials will be
necessary if we want to overcome this problem.
Our aim is to discuss the main characteristics and applications
of the wide variety of vitreous substitutes that are currently used
in clinical practice, before going on to address the development
of new hydrogels that have been presented as promising alterna-
tives for the optimization of vitreous substitution.
2. Composition and Functions of the Vitreous
The vitreous is a gelatinous structure that is composed of 98%
water.[3,4] It protects the adjacent structures and tissues from trau-
mas, as well as permitting the circulation of nutrients and so-
lutes, and controlling the oxygen tension within the eye. It helps
to maintain the shape of the ocular globe, as well as keeping the
crystalline lens and the retina in their place.[3,6] The main compo-
nents of the vitreous humour, as well as the major characteristics
of the aforementioned components are outlined below.
2.1. Proteins
Proteins represent a small percentage of the overall content of
the vitreous components. The majority of the soluble proteins
are albumin (40%), with the other important components includ-
ing immunoglobulins and iron-binding proteins such as trans-
ferrin, which helps to reduce iron toxicity in the case of small
hemorrhages.[1,6,7] With regards to insoluble proteins, collagens
are the most abundant. There are different types of proteins
which play a major role in the vitreous structure.[4,8]
2.2. Glycosaminoglycans (GAGs)
GAGs, which are extracellular polysaccharides are a key compo-
nent of the vitreous structure, and these are mainly divided into
three types—hyaluronic acid, heparan sulfate, and chondroitin
sulfate.[1]
2.2.1. Hyaluronic Acid (HA)
HA is a major component of the vitreous, forming 3D structures
with collagen. The fact that it does not contain sulfate makes
it distinguishable from the other GAGs, and this also means
that it does not attach to proteins to form a proteoglycan.[1] The
highest concentrations of hyaluronan molecules are found in
the posterior vitreous cortex.[6,9–11] The HA preparations consist
of molecules with greater variability in terms of hydrodynamic
size, and these are a relevant component in determining vitre-
ous viscosity.[12]
2.2.2. Chondroitin Sulfate (CS)
CS is a sulfated GAG, which consists of a chain of alternating sug-
ars (N-acetylgalactosamine and glucuronic acid). It constitutes a
major component of the extracellular matrix and is also present
in the vitreous, appearing in the form of the proteoglycans versi-
can and type IX collagen.[4,11] CS is used to preserve the integrity
of the vitreous and provide resistance against compression.[1]
2.2.3. Heparan Sulfate (HS)
HS is a renewable proteoglycan, which ensures that there is ad-
equate spacing between the collagen fibrils, nonetheless, small
amounts of HS are present in the vitreous.[13] It also enhances
the regulation of angiogenesis and blood coagulation, as well as
maintaining vitreo-retinal adhesion.[4]
2.3. Glucose, Lactic Acid, and Antioxidants
Due to the important role that the vitreous plays in the cellu-
lar metabolism of ocular tissues, its components include several
substances that act as subtracts for metabolism, such as glucose
and lactic acid, which are necessary to support the metabolism
in the surrounding tissues.[4,6] In addition, the vitreous acts as a
reservoir of glucose for the ciliary body.[14]
On the other hand, ascorbic acid is a crucial antioxidant
for lens and retinal metabolism, in particular it is used as a
metabolic buffer in potassium homeostasis. Furthermore, it may
also inhibit neovascularization and increase the proliferation of
hyalocytes.[15–17]
2.4. Cells and Enzymes
There are three types of cells that are found in the vitreous
body: hyalocytes, fibrocytes/fibroblasts, and macrophages.[6,18,19]
The main functions of these cells are related to the creation,
regulation, and degradation of the vitreous matrix. Several en-
zymes have been isolated, which include hyaluronidase, serine
proteases, and renin-angiotensin-converting enzyme.[20–22]
3. Vitreous Substitutes in Clinical Practice
Vitreous substitutes must have physical and biological prop-
erties that make them suitable for use in clinical practice. In
terms of their physical properties, ideal vitreous substitutes will
be hydrophilic and insoluble in water, easy to manipulate dur-
ing surgery, clear and transparent to facilitate visualization, and
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Figure 1. Gas injection in pneummoretinopexy. A) Example of a superior
detachment and injection with the patient lying in the supine position
(face-up). B) The patient is placed in an upright position and the bubble
tamponades the break. Created with BioRender.com.
they will also have a refractive index that is similar to the hu-
man vitreous. In addition, these must remain stable when in-
jected through a small syringe, as well as ensuring adequate
surface tension in the attempt to seal the retinal break.[2,23] On
the other hand, and in terms of their biological properties, the
ideal vitreous substitutes will be biodegradable and biocompati-
ble, biologically and chemically inert, and they will not block the
aqueous drainage. Furthermore, they must be nontoxic to retinal
tissues.[6,23]
An ideal vitreous substitute does not yet exist; all of them of-
fer advantages and drawbacks, which may or may not make them
suitable depending on the clinical situation. Those currently used
in clinical practice are divided into different categories based
on different properties. Specifically, these are divided into gases
(air, SF6, C3F8, and C2F6) and liquids (salt solution, silicon oils
(SO), perfluorocarbon liquids, and semi fluorinated alkanes). The
characteristics of each individual group, as well as their clin-
ical indications have been outlined in detail in the following
sections.
3.1. Gases
Ohm was the first to describe intraocular gas use in 1911.[24] Sev-
eral indications for its use were described, with the first of these
being its use as an internal tamponade.[25] It also proves useful in
unfolding and folding the retina, as well as in improving its post-
operative visualization and replacing the globe volume to pre-
vent fluid movement into retinal breaks. Gas is also used in sev-
eral techniques: pneummoretinopexy (Figure 1); the pars plana
vitrectomy for retinal detachment (RD), with and without scle-
ral buckle, to flatten the retina; subretinal blood displacement in
macular hemorrhages; and postvitrectomy liquid–gas exchange
in previously vitrectomized eyes.[26]
Postoperative care is very important in these patients. Prone
(face-down) positioning must commence as soon as possible
after the vitrectomy procedure has been performed. This is
crucial in preventing any shift of the reattached retina. Moreover,
it decreases the contact between the posterior surface of the lens
with the gas bubble in phakic patients (the bubble is situated
towards the retina); therefore, reducing the risk of cataract
formation. Positioning may also vary depending on the location
of the retinal break, usually lying on the opposite side of the
break.
The most widely used intraocular gases are sulfur hexafluoride
(SF6) and perfluoropropane (C3F8). These are nontoxic and inert
gases that are insoluble in the aqueous humour, and they boast
a lower water solubility than nitrogen therefore allowing them to
expand.[27] The decision as to which one of these gases is to be
used will be based on the tamponade duration and the surgeon’s
preferences, taking into consideration the type and location of the
retinal break.[28]
It is generally accepted that SF6 can be used in uncomplicated
primary RD. However, if a final tamponade action is necessary,
based on the results from “The Silicone Study”, in which the
results in patients with RD and proliferative vitreoretinopathy
(PVR), the pars plana vitrectomy with either C3F8 gas or SO tam-
ponades were favorable.[29] However, the clear advantage of using
gases is that it is not necessary to remove them.
There are three stages in the absorption of the intraocular gas:
expansion of the gas when injected, nitrogen equilibrium, and
dissolution.[30] Gases may be absorbed by diffusion across the
retina into the blood stream, or they may be dissolved into the
aqueous humour, and removed through the anterior chamber.[31]
The absorption of these gases demonstrates first-order pharma-
cokinetics, with small volumes lasting in the intraocular cavity
for days or weeks depending on the gas used.[30]
Knowledge of the kinetics of these gases, as detailed in Table 1,
comes mostly from animal models and small studies in which
indirect measurements have been taken in humans.[30–35] These
studies may not be representative of current practice, especially
with regards to the duration of the air bubble in the posterior
chamber of the eye, which is perceived to be longer in clinical
settings than in theoretical ones.[36,37] The half-life of intraocular
gases is shorter in aphakic eyes than in phakic eyes, due to the in-
creased convection in the vitreous cavity.[38] Following the vitrec-
tomy procedure, convection currents appear in the aphakic eye,
which accelerate the absorption rate. In phakic eyes with normal
vitreous, there are much fewer convection currents; therefore,
the expansion and absorption of long-acting gases is slower.[30]
3.1.1. Air
Room air tamponade applied using non-expansible gas begins
to shrink immediately after injection as it dissolves in the
vitreous.[28] This offers an advantage over other long-lasting gases
as it requires shorter prone positioning, allowing for a faster re-
covery of vision and less adverse effects.[41]
The half-life of a room air tamponade was 1.6 d in phakic
eyes[30] with a longevity of 5 d, but recent clinical impressions
have suggested that air remains in the vitreous cavity for a longer
period of time. In a recent retrospective cohort study, a half-life
of 3.3 d with a longevity of 11.4 d was determined.[37]
3.1.2. Other Gases: SF6, C2F6, C3F8
Sulfur hexafluoride (SF6) and perfluoropropane (C3F8) are the
most commonly used intraocular gases in clinical practice, com-
pared to hexafluoroethane (C2F6) which is much less frequently
used.[36]
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Given that these gases boast a lower water solubility than ni-
trogen, they tend to expand to at least twice the volume of the gas
injected, as a result, nonexpansile or minimally expansile mix-
ture of gas is preferable in order to prevent adverse effects such
as intraocular pressure elevation (IOP).[28]
Water solubility varies depending on the carbon chain length.
The longer the carbon chain, the lower the solubility in water;
therefore, resulting in a longer intraocular longevity:[42] A mix-
ture of 10% C3F8 had a half-life of 5.7 d in phakic and 4.3 d in
pseudophakic eyes.[30] A mixture of 20% SF6 had a half-life of 2.8
d in phakic eyes. The half-life of C2F6 was not measured; how-
ever, a longevity of 34 d was determined in the vitreous cavity.[36]
Certain postoperative complications have been reported
following the use of intraocular gas, however, most of these
can be prevented by taking greater care when undertaking the
surgical procedure. For example, gas could go under the retina
although this is preventable, or gas could become entrapped at
the injection site.
One of the most frequent complications is the formation
of cataracts due to the gas coming into contact with the crys-
talline lens.[43] Raised intraocular pressure may occur, but this
tends to happen on the first postoperative day, and its cause has
been attributed to the expansion of the bubble or to an over-
filled eye. On the contrary, hypotony may occur if there is any
gas leakage from the sclerotomies. Other complications include
the presence of gas in the anterior chamber, secondary corneal
decompensation,[44] which is more frequent in aphakic patients,
and non-intact posterior capsule. In pseudophakic patients, in-
traocular lens capture may occur due to it being pushed forward
into the anterior chamber.[45,46]
3.2. Liquids
Different liquid vitreous substitutes are used in clinical practice.
The main groups and their major characteristics are depicted in
Table 2.
3.2.1. Salt Solutions
Salt solutions have similar characteristics to aqueous humour in
terms of their density, refractive index and transparency.[3] In the
clinical setting, these are used on a temporary basis during the
exchange with air or liquids as their low surface tension means
that these do not have tamponade properties.[4]
3.2.2. Silicon Oil
Silicon oil (SO) is a polymerized siloxane with organic side
chains. It belongs to the class of synthetic organosilicon com-
pounds and is a repetition of the –[R2Si–O]– group in which R is
the organic side chain.[47] Specifically, SOs used as vitreous sub-
stitutes are polymers of polydimethylsiloxane (PDMS).
In contrast to silicone rubber, polymer chains are shorter, and
given the lack of chemical cross-linking between them, these
present in a liquid form. They are hydrophobic substances with
a specific gravity, which is slightly lower than water, and a re-
fractive index that is higher than that of the vitreous.[48] These
are available in different viscosities, which is measured in centis-
tokes (cSt), and which ranges from 1000 to 5000 cSt in clinical
practice.
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Table 2. Physical properties of liquid vitreous substitutes and clinical indications.
Product Specific gravity
[g cm−3]
Viscosity [cSt] Refractive index Indications
A. SALT SOLUTIONS
BSS 1 Temporary replacement during air/oil exchange
B. SILICON OILS
SO 1000 cSt 0.97 1000 1.4 Complex RD associated with PVR
Giant tear, RD with PVR
Traumatic RD with PVR
Recurrent RD with breaks involving the lower quadrants
RD associated with severe proliferative diabetic retinopathy
RD associated with macular hole in pathologic myopia
Pediatric RD
RD associated with viral retinitis
Posttraumatic endophthalmitis
SO 2000 cSt 0.97 2000 1.4
SO 5000 cSt 0.97 5000 1.4
C. PERFLUOROCARBON LIQUIDS
Perfluorooctane (C8F18) 1.76 0.69 1.27 Primary Rhegmatogenous RD
Complicated RD with PVR
Giant tear RD with PVR
RD associated with disc coloboma, Dislocated lens, Suprachoroidal
hemorrhage
Perfluorodecalin (C10F18) 1.94 2.7 1.33
Perfluoroperhydrophenanthrene (C14F24) 2.03 8.03 1.31
Octafluoropropane (C3F8) 1.6 0.465 1.22
iv.SEMIFLUORINATED ALKANES
Perfluorohexyloctane (F6H8) 1.35 3.44 1.387
D. SFA-SO combinations
(a) Double fillings
(b) Heavy Silicon Oils
Densiron-68 1.06 1387 1.39 RD associated with inferior tears and PVR
Oxane HD 1.02 3300 1.4
HWS 46–3000 1.12 2903 1.37
Since the 1960s, SO have been used as short and long-term vit-
reous substitutes because of their transparency, low surface ten-
sion, buoyancy, and low toxicity. The role of SO in clinical practice
was defined by “The Silicone Study”,[49,50] a multicentre prospec-
tive randomized clinical trial that compared the effect of SO to
long-acting intraocular gases (SF6 and C3F8) in the management
of complex RDs associated with severe PVR. Globally, SO was
demonstrated to be more effective than SF6, and equally as ef-
fective as C3F8 in reattaching the retina.
[49] In addition, SO and
C3F8 produced very similar results in terms of the improvement
of visual function and the low complication rates. Furthermore,
the ophthalmologist‘s preference or the need for the patient to
take a flight soon after the intervention could be reasons for
using SO.[1]
The use of SO in giant tears without PVR is still being debated.
In this sense, good anatomic success has been reported with SO
and gases. Generally speaking, SO is the most used agent in
Europe, while in the United States some ophthalmologists still
have a preference for intraocular gas.[51]
SO tamponade tends to be administered at the primary vit-
rectomy for traction RD associated with severe proliferative di-
abetic retinopathy.[52] However, to date, no clinical trials have
adequately evaluated its efficacy in this use. In addition, with
regards to the treatment of RDs in viral retinitis, SO offers
long-term internal tamponade, therefore decreasing the risk of
re-detachment.[53,54]
Regarding the pediatric population, the main indications for
the use of SO tamponade are RDs associated with retinopathy
of prematurity, trauma, congenital anomaly, and myopia. In the
case of severe traumatisms, SO internal tamponade may help to
flatten the retina and prevent hemorrhage, which would increase
the risk of PVR.[55]
Finally, it has been argued that SOs have certain antimicrobial
activity, which is why they are usually used as a tamponade in
posttraumatic endophthalmitis cases.[56]
With regards to the disadvantages of SOs, these include the
need for optical adjustments to be made due to the different re-
fractive index when compared to the natural vitreous body, and
the less effective nature of the use of the tamponade in treating
inferior retina breaks due to its low specific gravity.[57,58]
Furthermore, serious complications such as retinal toxicity,[59]
optical neuropathy,[60] or glaucoma [61] have been reported with
the use of SO, some of which are related to the emulsification
of SO, especially in long-term use. This emulsification leads
the original SO bubble to break down into smaller droplets,
resulting in retinal inflammation by inducing a macrophagic
response.[62]
SOs must be removed as soon as they have fulfilled their
purpose, and when it is established that further retention could
increase the risk of complications (Figure 2). This removal is
generally recommended within a six-month period after the
intervention.
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Figure 2. Silicone oil (SO) removal through active suction with machine
assistance. Created with BioRender.com.
3.2.3. Perfluorocarbon Liquids
Perfluorocarbon liquids (PFCLs) are fluorine-substituted hydro-
carbons, which are clear, colorless and odorless liquids. These
synthetic compounds are characterized by a high specific grav-
ity, between 1.7 and 2.1 g cm−3, twice as high as water, and
their refractive index is similar to that of the vitreous humour.[63]
They are insoluble in water and poorly soluble in SOs. The most
commonly used PFCLs in clinical practice are perfluorodecalin
(C10F18), perfluoroperhydrophenanthrene (C14F24), perfluorooc-
tane (C8F18 and octafluoropropane (C3F8).
[4] Historically, these
were first investigated as blood substitutes due to their exten-
sive capacity for transporting and releasing oxygen and carbon
dioxide.[64]
In the clinical setting, the use of PFCLs has improved the vi-
sual outcomes and the anatomic success rate in PVR surgical
procedures.[65–68] PFCLs provide the best currently available inter-
nal tamponade during membrane dissection. Similarly, the use
of PFCLs in treating giant-tear RD has improved the anatomic
success rate by over 90%.[66] The PFCLs allow for the reposition-
ing of the folded flap, enabling direct PFCL-SO exchange in order
to prevent the posterior flap from slipping.
PFCLs also offer several advantages in the treatment of trau-
matic RD, including the stabilization of the retina during the
vitrectomy procedure, the displacement of preretinal, subretinal,
and suprachoroidal blood, the elimination of incarcerated vitre-
ous or retina, and the maintenance of a transparent medium for
visualization during surgery.[69]
The use of PFCLs in other ophthalmic pathologies has already
been proved, for example in cases of RD associated with diabetic
retinopathy,[70] detachment associated with disc coloboma,[71] de-
tachment from retinopathy of prematurity,[72] vitrectomy for en-
dophthalmitis, displacement of submacular hemorrhage during
surgical drainage, and the excision of subretinal membranes.[73]
Figure 3. Perfluorocarbon liquid (PFCL) – silicone oil (SO) exchange. SO
is filled progressively superiorly, while PFCL is extruded through the flute
needle placed within the PFCL bubble. Created with BioRender.com.
With regards to the safety of PFCLs, in recent years, several
cases of retinotoxicity caused by perfluorooctane have been re-
ported worldwide. In this regard, it is necessary for strict proto-
cols to be established to determine the cytotoxicity of intraocular
medical devices in order to ensure the adequate quality of these
products.[74] Nowadays, their use is limited to the intraoperative
setting because of their long-term toxicity, and as a result they
have been exchanged with SO (Figure 3) or another long-term
vitreous substitutes.[75–77]
3.2.4. Semifluorinated Alkanes
Semifluorinated alkanes (SFAs) were identified in the 2000 s
as an alternative to PFCLs given the presumption that the lat-
ter could cause retinal toxicity due to their high specific density.
Moreover, SFAs maintain properties such as inertness, biocom-
patibility, interface tensions, etc., containing both perfluorocar-
bon and hydrocarbon segments. They have lower densities com-
pared to PFCLs, ranging from 1.1 to 1.7 g cm−3, and they are
soluble in PFCLs, hydrocarbons and SO. They also have very low
surface and interface tensions.[76]
The shorter the perfluoroalkyl chains and/or the longer the
alkyl chain, the more toxic the semifluorinated alkanes are. Im-
purities containing –CHF groups must also be taken into ac-
count, given that hydrogen fluoride groups can be eliminated in
the presence of nucleophilic bases, resulting in toxic alkenes.[76]
SFAs were initially used as SO solvent, and later as tem-
porary endotamponades when it was observed that SO was
ineffective.[78] The most common problems related to the use of
SFAs are cataracts and emulsification. Nowadays, SFAs tend to
be mixed with SO.
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3.2.5. Silicon Oils and Semifluorinated Alkanes Combination
The combined use of SO and SFAs tamponade agents has been
widely studied, with the idea of bringing together the high vis-
cosity of SO and the high specific gravity of SFAs. This mixture
generates vitreous substitutes that boast good tamponade prop-
erties and minimal emulsification.[79]
Depending on the proportion of SO and SFAs included in the
mixture, it is possible to obtain homogeneous solutions (heavy
silicone oils) or separated solutions (double fillings).[80]
Heavy silicone oils—Heavy silicone oils (HSO) are homoge-
neous solutions that are heavier than water and that are formed
by combining SO and SFAs. In clinical practice, these are used
for treating complicated RDs, especially those which involve in-
ferior PVR. There are three prefabricated HSOs currently on the
market: Densiron 68, Oxane HD, and HWS 46–3000.
Densiron 68 (Fluoron Co, Ulm, Germany) is a mixture
of 30.5% SFA F6H8 (perfluorohexyloctane) with 69.5% SO,
5000 cSt.[78] By adding SO, the viscosity of F6H8 increases from
2.5 to almost 1400 mPa s, reducing its dispersion tendency, which
is believed to cause the problems derived from the long-term use
of F6H8. It has a specific gravity of 1.06 g cm
−3 and a refractive
index of 1.387.
Oxane HD (Bausch & Lomb, Toulouse, France) is a mixture of
88.1% Oxane 5700, a 5000 mPa s SO, with 11.9% RMN3, a par-
tially fluorinated olefin. It has a slightly superior specific grav-
ity and refractive index than water, 1.02 g cm−3 and 1.4, respec-
tively. It is the most viscous, 3800 mPa s, and least heavy HSO of
the three products. Because of its lower specific gravity, slightly
higher re-detachment rates were found when using this HSO.[81]
The last commercialized HSO is called HWS 46–3000, which
is a mixture of 45% ultrapurified SO 100 000 (viscosity 97 100
mPa s and specific gravity 0.977 g cm−3) and 55% perfluorobutyl-
hexane (F4H6) a semifluorinated alkane (viscosity 1.28 mPa s and
specific gravity of 1.254 g cm−3). The resulting solution (specific
gravity of 1.105 g cm−3 and a viscosity of 3109 mPa s) is homo-
geneous and stable in the presence of water, air or PFCLs. It is
the heaviest and most viscous mixture of the three. In the pilot
study by Rizzo et al., high success and low complication rates
were achieved when HWS 46–3000 was used as a long-term tam-
ponade (1–3 months), even though, due to its higher viscosity,
handling this substance may be more difficult, e.g., when remov-
ing it.[75]
Densiron 68, Oxane and HWS 46–3000 have shown promising
results in the treatment of RDs associated with inferior tears.[82]
However, in a prospective, multicentered, randomized controlled
trial (HSO Study) that compared the effect of heavy tamponade
(Densiron 68) and conventional SO in eyes with inferior and pos-
terior PVR grade C or above, researchers concluded that there
were no significant benefits to using heavy tamponade instead of
conventional SOs in these cases.[29]
Double fillings—Double fillings are heterogeneous solutions
in which the SFA sinks and the SO floats due to its specific
gravity, meaning that they are able to provide superior and infe-
rior tamponades simultaneously. The most commonly used SFA
is perfluorohexyloctane (F6H8). The amount of F6H8 is much
greater than the amount that can be dissolved by SO; therefore,
the top part of the bubble consists of SO saturated with dissolved
F6H8, whereas the bottom part of the bubble is pure F6H8. The
Table 3. Advantages and limitations of the vitreous substitutes used in
clinical practice.
Advantages Limitations




- Prone positioning after vitrectomy
- Expansile gases can produce
intraocular pressure elevation (IOP)
Silicone Oils - Transparency




- Must be removed within a 6-month
period
- Optical adjustments may be
required
- Less effective tamponade of the









- Stabilization of the
retina during
vitrectomy
- Limited to intraoperative setting
- Long-term toxicity




than PFCLs due to its
lower specific density











- Less tendency to
disperse
- Difficult to handle due to its viscosity
- Must be removed within a 2-month
period.
most commonly reported combination is F6H8 mixed with 1000
cSt SO in a 3:7 proportion.[83,84] A combined internal tamponade
of F6H8 and SO may be useful for treating complicated RD with
breaks involving the retina’s lower quadrants.[85]
In order to clarify all of the advantages and limitations of the
vitreous substitutes that are currently used in clinical practice,
these characteristics have been included in Table 3.
4. Influence of Vitreous Substitution on
Pharmacokinetics of Intravitreal Drugs
When the vitreous is substituted with SO, 80% of the vitreous cav-
ity will be filled with the tamponade, while the rest will be replen-
ished with aqueous humour and some vitreous remnants may be
present. In the case of inert gas substitutes, the proportion that
is to be refilled with the aqueous humour will increase as the gas
disappears, and the time it takes to totally disappear will differ de-
pending on the type of gas (Table 1). Artificial substitutes that are
currently used in clinical practice differ in terms of their vitreous
composition, and this may affect the pharmacokinetics of intrav-
itreally injected drugs.[86] Most of these drugs are water-soluble
and will only dissolve in the vitreous aqueous phase. To the best
of our knowledge, very few intravitreal pharmacokinetic studies
have been conducted on tamponade animal eye models[87,88] in
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which SO was used as the vitreous substituent. In this sense, Xu
et. al investigated the bevacizumab injection (1.25 mg/0.05 mL)
in a rabbit model, observing that silicone acted as a temporary
depot for controlled drug delivery, delaying drug distribution into
the remaining vitreous aqueous phase, where the drug dissolved,
before being further distributed into the surrounding tissues.
Therefore, it is anticipated that the drug concentration-time pro-
files will change between the native and filled vitreous. However,
given the lack of internal control the intravitreal clearance or half-
life differences between SO-vitreous and the control healthy eye
were not determined in those studies.[87,88] For ethical reasons it
is not possible to perform these types of pharmacokinetic studies
in patients. Nevertheless, a few studies have evaluated the safety
and efficacy of treatment versus no-treatment in SO-filled eyes
with antivirals[89] or bevacizumab injections,[90,91] observing pos-
itive clinical outcomes in the treated patients. Several other case
reports have shown that the Ozurdex implant (dexamethasone
0.7 mg loaded in a biodegradable sustained-release intravitreal
implant (Allergan Inc., Irvine, CA)) appears to be tolerated by and
beneficial to patients with SO tamponade.[92–94] However, it must
be noted that the reported clinical studies are based on a limited
number of patients. The drug release from the implant will de-
pend on the phase in which said implant is located, that is to say
the aqueous phase or the SO/gas phase, as this release will only
be possible in a medium in which the drug can be dissolved. In
the case of acting-gas tamponade, the release may also be depen-
dent on the timing of the gas disappearing. Moreover, the drug
release from the implant may be delayed in the filled-eye, and
longer drug levels may be maintained, nonetheless, further in-
vestigations on an animal models are required.[95]
Overall, there is still a lack of quantitative data on the effect of
the vitreous substituents on intravitreal pharmacokinetics. Fur-
ther pharmacokinetic studies must be conducted in order to clar-
ify their effect on the drug concentrations following intravitreal
administration, for both drug solutions and implants.
5. Experimental Vitreous Substitutes: Hydrogels
There are still numerous inconveniences and limitations to the
use of currently available vitreous substitutes in clinical practice.
Consequently, the search for new biomaterials that can be used
to achieve the ideal vitreous substitute still continues. Previous
research attempted to produce vitreous substitutes that boasted
similar physiological properties and molecular structure to the
vitreous body. The limits of this approach included the toxicity
of the compounds and their incapacity to provide sufficient in-
ternal tamponade for vitreous replacement surgery.[96] In order
to overcome these drawbacks, recent research has focused on de-
veloping biocompatible, biodegradable, and injectable hydrogels
(natural, synthetic, and smart), which will also act as medium and
long-term internal tamponade agents.[2] Hydrogels do not have to
be removed after a certain period of time, therefore overcoming
one of the main inconveniences related to this procedure. In ad-
dition, depending on the types of polymers used for their synthe-
sis, some of their properties can be optimized. Specifically, their
viscosity, porosity, good mechanical strength, and the possibility
of drug encapsulation make these advantageous for their clinical
use in patients. Main hydrogels which have been developed as vit-
reous substitutes in recent years have been outlined in Table 4.
5.1. Natural Hydrogels
The use of HA and collagen as vitreous substitutes has been eval-
uated due to their great biocompatibility and given that these are
the main components of the vitreous. However, they have a poor
tamponade effect and a limited retention time in vivo compar-
ing to the results produced by synthetic and smart hydrogels,
due to the molecules tendency towards degradation and their low
viscosity.[23,97]
To increase retention time, HA has been cross-linked through
UV and dihydrazide, resulting in biocompatible hydrogels that
present good transparency, viscosity, and tamponade effect
thanks to their hydrophilic properties, nonetheless, these mate-
rials still present relatively short-term stability.[99,103] In addition,
cross-linked hyaluronate formulations and combinations of HA
with other polymers, such as microbial anionic polysaccharide
gellan have also been tested. However, due to the instability of
the physical crosslinks, these combinations are not available for
long-term use.[97,98,100,101]
Aiming to improve this feature, Raia et al. synthesized silk and
HA composite hydrogels by cross-linking the tyrosine residues
native to silk fibroin and tyramine-conjugated HA. In this sense,
the composite silk-HA hydrogel retained the favorable properties
of each of the polymers. Consequently, the better control of the
water content in the composite matrix exerted by HA and the slow
proteolytic degradation of the silk resulted in longer stability and
durability.[125]
Additionally, Uesugi et al. used a natural polymer, which was
not based on collagen or HA as a vitreous substitute. Specifi-
cally, they reported the use of PanaceaGel SPG-178 (0.1%), a self-
assembling gel, the main component of which is 13 amino acid
synthetic peptide. This gel can be injected through a 27-gauge
needle and its refractive index, visible light transmission rate, and
rheological properties are similar to those of human vitreous. In
addition, they carried out a three-month in vivo study in rabbits
in which good biocompatibility and no toxicity were observed.[102]
Nevertheless, rapid degradation remains a major problem for
this type of substitutes, as biomaterials tend to degrade and
change their physicomechanical properties in a short period of
time. This is a considerable drawback given that the ideal vitre-
ous substitutes must be stable for long periods of time, preferably
over three months.[2,6]
5.2. Synthetic Hydrogels
Polymeric hydrogels are the next step towards producing the
ideal vitreous substitute. These materials are networks of cross-
linked hydrophilic polymer chains with extensive swelling, ab-
sorbing several times their own weight in water.[126,127] They have
a good level of transparency, biocompatibility, and present vis-
coelastic properties that are similar to the vitreous body, imitating
its biofunctionality.[128]
Poly(1-vinyl-2-pyrrolidone) (PVP) was the first synthetic poly-
mer to be tested as a potential vitreous substitute. The most
commonly reported adverse effects were vitreous opacification
and inflammation reaction, resulting in early PVP degrada-
tion due to phagocytosis.[129] In addition, 1-vinyl-2-pyrrolidone
(VP) monomer was polymerized with divinyl glycol (DVG) as a
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Table 4. Hydrogels developed as vitreous substitutes and their main characteristics.
Hydrogels Polymer content [%] Refractive index Light transmittance [%] In vivo studies Reference
Natural polymers
Gellan and hyaluronic acid 1 85–95 no [97]
Methacrylated gellan gum 1 no [98]
Hyaluronic acid 1 1.338 rabbits [99]
Hyaluronic acid 3 1.341 rabbits [100]
Hyaluronic acid 1–2.2 1.32–1.34 rabbits [101]
Peptide gel 0.10 1.3339 96.7 rabbits [102]
Hyaluronic acid 1 1.32–1.33 rabbits [103]
Hyaluronic acid 1 1.336 75–91 no [23]
Synthetic polymers
Polyvinyl alcohol methacrylate 9 no [104]
Polyvinyl alcohol 7 macaques [105]
Polyvinyl alcohol 4 85 no [106]
Poly(ethylene glycol) 5 1.339 rabbits [107]
Polyvinyl alcohol 5 no [108]
Polyvinyl alcohol 1–7 1.3361 93 rabbits [109]
Polyvinyl alcohol 4 1.3420 no [110]
Acrylic acid and acrylamide 1.25 –1.75 no [111]
Poly N-acryloyl glycinamide-polycarboxybetaine acrylamide 1.60 1.3354 93.2 rabbits [112]
Smart hydrogels
WTG-127 89.3 rabbits [113]
Poly(ethylene glycol) 25 1.353 >90 no [114]
Poly(ethylene glycol) 10 1.3325 rabbits [115]
Sulfobetaine methacrylamide and acryloyl cystamine monomers 5 >90 rabbits [116]




Poly(ethylene glycol) 0.4–0.7 rabbits [119]
Polymethacrylamide and poly-methacrylate 0.9–1.8 1.3345–1.3348 >95 no [120]
Hydroxypropyl chitosan and alginate dialdehyde 1–3 1.3348 >80 rabbits [121]
Poly(ethylene glycol), poly(propylene glycol), and
poly(𝜖-caprolactone)
3–12 1.339–1.344 rabbits [122]
Poly(ethylene glycol) methacrylate and poly(ethylene glycol)
diacrylate




1.3355–1.3370 >83 rabbits [124]
cross-linking agent in order to obtain a transparent hydrogel with
a similar density and viscosity to the vitreous body.[129] Finally,
VP was also co-polymerized with 2-hydroxyethyl methacrylate
(HEMA) using diallyl ether (DAE) as a cross-linking agent, re-
sulting in a clear and transparent gel with mechanical properties
close to those of the vitreous, however, the main inconvenience
was that the elastic properties were reduced or even lost when
injected.[130]
Polyacrylamide (PAA) has been synthesized by the polymer-
ization of acrylamide, a toxic and carcinogenic substance, with a
disulfide cross-linking agent. However, this polymerization pro-
cess highly improves its biocompatibility. PAA presents good bio-
compatibility and long-term stability, as well as offering a similar
viscosity and density to the vitreous. With regards to adverse reac-
tions, severe ocular inflammation and vitreous opacification have
been reported.[131]
Poly(2-hydroxyethylacrylate) (PHEA) presented very good
physical properties; however, due to the emergence of inflamma-
tory reactions, as well as cataract and glaucoma this substance is
no longer being investigated.[4,6]
All of the aforementioned polymers presented complications
related to inflammation and toxicity. As a result, other polymers
such as poly(glyceryl methacrylate) (PGMA) and hydroxypropyl
methylcellulose (HPMC) were investigated; however, these did
not reach the clinical study stage due to their short degradation
time.[132,133]
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In recent years, further polymer-based hydrogels, which are
presented below, have been synthesized in order to overcome
some of the previously mentioned drawbacks.
Poly(vinyl alcohol) (PVA) presents good biocompatibility, as
well as optical and rheological properties. In addition, it cannot be
differentiated from the natural vitreous during the first months
after the injection. All these features make it an optimum vitreous
substitute and its rheological characteristics and diffusion behav-
ior can be further improved by adding trisodium-triphosphate as
a cross-linking agent. However, there is still insufficient data re-
garding its tamponade properties.[105,106,108–110]
Poly(vinyl alcohol methacrylate) (PVA-MA) is more hydropho-
bic than PVA due to its increased metacrylate content; however,
the polymer’s backbone is hydrophilic enough to form a hydro-
gel. The inclusion of a photoinitiator, which forms a gel net-
work after irradiation at 365 nm is a unique characteristic of this
gel. The degree of gelification can be regulated by light inten-
sity and polymer concentration. Nevertheless, more studies are
necessary in order to evaluate the vitreous biocompatibility of
PVA-MA.[104]
Copolymers of PAA (CPA) are derived from PAA; however,
these acquire better gelification properties, through polymeriza-
tion after a reduction of the disulfide cross-linking bridges. These
polymers have similar viscoelastic properties and refractive index
to the vitreous, as well as good compatibility and a lack of signif-
icant ocular toxicity, positioning itself as a good alternative for
long-term substitution.[131]
Poly(2-hydroxylethyl methacrylate) (pHEMA) presents solid
properties, meaning that its implantation proves difficult. Its ad-
ministration through a small hole during the vitreo-retinal surgi-
cal procedure is not possible, requiring a surgical incision, which
makes the surgery more complex as well as producing greater
trauma to the eye.[134,135]
Poly(ethylene glycol) (PEG) in aqueous solution at 5 wt% was
tested in an in vivo rabbit model. It boasted optical and physical
characteristics similar to natural vitreous and was well tolerated.
However, the solution was not retained throughout the postoper-
ative period, meaning that the residence time would have to be
increased through polymer cross-linking.[107]
Beta cyclodextrin polymeric interacts with hydrophobic poly
{(2-acrylamido-2-methyl-1-propanesulfonic acid sodium salt)-co-
[6-(acrylamido)-N-adamantylhexaneamide]} when mixed in wa-
ter to create a hydrogel. Bhöm et al. synthesized this gel and
tested it in vitro as a vitreous substitute which presented biocom-
patibility. However, the authors concluded that it was necessary
to reconsider the use of this hydrogel due to the cytotoxic effects
caused by the adamantyl-functionalized polymer.[136]
Davis et al. used acrylic acid in combination with acrylamide
in order to synthesize a hydrogel with bis-acryloylcystamine as
a reversible cross-linker. The formulation was tested in vitro,
and it remained optically clear, presenting biocompatibility.
However, it caused an inflammatory response in the retinal
cells.[111]
Poly N-acryloyl glycinamide-poly carboxy betaine acrylamide is
a supramolecular binary hydrogel which is formed by copolymer-
ization of its two components, which are physically cross-linked
by dual amide hydrogen bonds, presenting an ultralow solid
content. Wang et al. demonstrated that it was biocompatible
and that its light transmittance and refractive index were very
close to those of the vitreous. In addition, they observed that
this hydrogel could be injected into the rabbits’ eyes using a
22G needle, with rapid recovery of the gelling network. After
a 16-week in vivo study, the hydrogel remained very stable,
without affecting any structure in the eye or producing adverse
effects. Consequently, after the necessary clinical trials have been
conducted, this hydrogel could be considered as an interesting
alternative for long-term vitreous substitution.[112]
5.3. Smart Hydrogels
Polymer-based hydrogels emerged as a promising alternative
for vitreous substitution. However, the mechanical properties of
most of these is modified during the injection process when they
are pushed through a small-gauge needle.[124] The shear degra-
dation causes the rupture of polymeric chains, resulting in loss
of elasticity and fluidification.[137]
As a result, smart hydrogels may constitute a potential alterna-
tive due to the fact that they can be prepared, stored and injected
as a solution and gelate in situ, via external stimuli.[138] These
hydrogels are held together by noncovalent interactions such
as electrostatics, hydrogen bonding, and hydrophobic forces.[139]
They can effectively dissipate mechanical energy due to their in-
herent reversibility and dynamism, which allows sol-to-gel tran-
sitions. These reversible transitions facilitate the injection proce-
dure as well as the possible future removal.[2,140]
In this way, Tao et al. developed an in situ chemically cross-
linked hydrogel system, which consisted of two components,
both based on multifunctional PEG but with complementarily
reactive end groups of thiol and active vinyl groups. The system,
when injected reacts via the Michael addition route and forms a
chemically cross-linked hydrogel in situ. It was tested in vivo in
rabbits, remaining transparent and stable for a 9-month period,
with no adverse effects. Therefore meaning that after successful
clinical trials have been conducted this hydrogel could be suitable
as a potential long-term vitreous substitute.[115]
Similarly, Chang et al. synthesized a zwitterionic poly-
mer poly(MPDSA-co-AC) as a copolymer of the sulfobetaine
methacrylamide and acryloyl cystamine monomers, providing
the zwitterionic components and the thiol functional groups,
respectively. The in situ gelation was also via the Michael addi-
tion route with PEGMA as the cross-linker. In vivo studies in
rabbits showed optimum transparency and biocompatibility but
only for a 2-month period.[116] Consequently, further studies will
be required in order to evaluate its potential use as long-term
substitute.
Continuing with in situ hydrogels, Hayashi et al. developed an
oligo-Tetra-PEG hydrogel, by mixing tetra-armed poly(ethylene
glycol) with thiol termini (Tetra-PEG-SH) and maleimide termini
(Tetra-PEG-MA) as a long-term vitreous substitute. The authors
demonstrated that this hydrogel was effective in the treatment
of RD in rabbits’ eyes for a period of one year without any
adverse effects. These results suggest that this could be used as
a long-term vitreous substitute once the necessary clinical trials
have been conducted.[119]
In this regard, Liang et al. combined polymethacrylamide
(PMAM) with the anionic nature of polymethacrylate (PMAA) to
make copolymers by using bis-methacryloyl cystamine (BMAC),
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introducing thiol groups for reversible crosslink. They stated that
copolymers with higher MAA content gelled faster, swelled more,
and had higher storage modulus compared to that of natural
vitreous. The authors confirmed the biocompatibility in vitro;
however, they did not provide any information on the in vivo
evaluation.[141]
For their part, Jiang et al. developed a hydrogel of hydrox-
ypropyl chitosan with alginate dialdehyde by crosslinking with
BMAC to introduce thiol groups for reversible crosslink. When
injected through a double-syringe injector with a Y-joint, the
substance formed an in situ gel in 1–3 min. It presented opti-
mum physical characteristics and rheological properties similar
to those of the vitreous and it proved biocompatible in vitro. How-
ever a 90-d in vivo rabbit study showed both a decrease in the
number of cones and rods in the rabbits’ eyes and a decline in
vision.[121]
Thermoresponsive hydrogels can be easily applied in clinical
practice as they can be injected in liquid form, at room tem-
perature, and undergo gelation in situ at physiological temper-
ature when administrated.[142] In this sense, it is necessary to
mention the studies carried out with Pluronic-127 and WTG-
127.[113,143] Pluronic-127 boasts promising physical properties,
showing a thermoreversible gelation behavior at concentrations
of 20 wt% and above, assuming liquid form when cold but form-
ing a clear gel at 21 °C.[144] Nevertheless, it was found to be un-
suitable for vitreous substitution due to the induction of severe
retinal toxicity.[143] On the other hand, WTG-127 was associated
with low stability and diffusion under the retina before gelation
was complete.[113]
In this sense, Annaka et al. developed a thermosensitive
hydrogel based on PEG end-capped with an octadecyl groups
(E10KDC18). This hydrogel was tested in vitro and in vivo, show-
ing the optimum requirements for clinical use: clarity and trans-
parency, biological and chemical inertness, nonabsorbable and
nonbiodegradable characteristics, refractive index similar to nat-
ural vitreous, sufficient rigidity to act as tamponade agent, and
ability to be injected through small-gauge needles. However, fur-
ther studies must be carried out in order to evaluate its long-term
biocompatibility.[114]
Continuing on with the idea of using thermoresponsive hy-
drogels as vitreous substitutes, some authors have synthesized a
biomimetic hydrogel composed of thiolated gellan as an analogue
of type II collagen and poly(methacrylamide-co-methacrylate-co-
bis(methacryloyl)cystamine), a polyelectrolyte, as an analogue of
hyaluronic acid.[117,118,124] This thermosensitive hydrogel can be
injected as a viscous solution at 45 °C. Once in the eye, this sub-
stance forms a physical gel in situ when it reaches body temper-
ature. The biocompatibility was tested in vitro, and, likewise, in
vivo studies were performed on rabbits, with satisfactory results
achieved in both cases with transparent corneas, and neither in-
flammation in the anterior segment, nor cataract development.
However, further studies are required in order to demonstrate
that it is a superior alternative to the materials that are currently
being used.[124]
The ideal smart hydrogel has not yet been created and in order
for the optimum smart hydrogel to be achieved, which satisfies
all of the required criteria, not only in preclinical studies, but also
in the adequately designed clinical trials, further studies will be
required.
5.4. Future Prospects in Vitreous Substitution
Hydrogels used as vitreous substitutes could also act as vehicles
to perform the slow and controlled release of certain drugs if
needed. In this sense, Tram et al. have synthesized vitreous sub-
stitute hydrogels composed of poly(ethylene glycol) methacrylate
(PEGMA) and poly(ethylene glycol) diacrylate (PEGDA), which
underwent in vitro and in vivo testing. These hydrogels deliver
vitamin C in order to protect ocular tissues, specifically the lens,
from oxidative stress and cataract formation after vitreous humor
removal, with the potential to reduce the cost of additional surg-
eries currently required for patients.[123] However, further studies
are needed to evaluate the clinical efficacy of this type of hydro-
gel in reducing oxidative stress and cataract formation in clinical
practice.
Liu et al. made important progress in the field of vitreous
substitution. These authors synthesized a tricomponent multi-
block thermogelling polymer, which consists of hydrophilic PEG,
poly(propylene glycol) (PPG) and poly(𝜖-caprolactone) (PCL) seg-
ments linked together via urethane bonds. They demonstrated
long-term biocompatibility in rabbit vitrectomy and nonhu-
man primate retinal detachment models. This hydrogel biode-
grades in the months after surgery and, likewise, it promotes
the reformation of a vitreous-like body that imitates the bio-
physical properties of the natural vitreous. Furthermore, it may
constitute a very interesting alternative for long-term vitreous
substitution.[122]
With regards to intravitreal administrations, it has been re-
ported that certain syringes may release silicone droplets, which
are interiorly recovered by certain kinds of silicones, causing vi-
sion impairment and sterile endophthalmitis. In this regard, in
recent times the regulatory agencies have published warnings
and as a consequence, further studies must be conducted to de-
velop new lubricant materials which do not cause these adverse
consequences.[145–147]
In the future, greater efforts must be made regarding the de-
velopment of regeneration-eliciting artificial vitreous that can
act as postsurgery tamponade agents, enhancing the total re-
generation of a vitreous-like body, with improved versatility and
efficiency.[148]
6. Conclusions
Vitreous substitution is indicated in the treatment of several
vitreo-retinal disorders. At present, there are a wide range of vitre-
ous substitutes available for use in clinical practice (gases and liq-
uids); however, despite boasting certain advantages, there are also
several inconveniencies in their use, which has meant that they
are not the ideal substances for this purpose. In recent years, re-
search has focused on the development of hydrogels based on dif-
ferent types of biomaterials. Specifically, considerable advances
have been made in the development of smart hydrogels, with
these representing the most promising alternative for vitreous
substitution due to the numerous advantages that are offered by
their reversible transition solution-gel. Despite the fact that many
biomaterials have been synthesized, to date, no hydrogel has ar-
rived to the clinical stage. Consequently, further studies must be
carried out in the area in order to find the ideal vitreous substitute
and introduce it into clinical practice.
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